NeuroOne Medical Technologies Corp NMTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NMTC is a good fit for your portfolio.
News
-
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
-
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
-
NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
-
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
-
NeuroOne® to Participate in the 36th Annual Roth Conference
-
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
-
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
Trading Information
- Previous Close Price
- $1.11
- Day Range
- $1.11–1.18
- 52-Week Range
- $0.85–2.00
- Bid/Ask
- $1.07 / $1.20
- Market Cap
- $29.30 Mil
- Volume/Avg
- 59,275 / 203,505
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.12
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 16
- Website
- https://www.n1mtc.com
Valuation
|
Metric
|
NMTC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.41 |
Price/Sales | 8.12 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NMTC
|
|---|---|
Quick Ratio | 2.33 |
Current Ratio | 3.68 |
Interest Coverage | — |
Quick Ratio
NMTC
Profitability
|
Metric
|
NMTC
|
|---|---|
Return on Assets (Normalized) | −169.08% |
Return on Equity (Normalized) | −218.38% |
Return on Invested Capital (Normalized) | −210.43% |
Return on Assets
NMTC
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Rvkrgqmy | Bsglh | $185.4 Bil | |
SYK
| Stryker Corp | Cnpqjgvflh | Yzds | $127.7 Bil | |
BSX
| Boston Scientific Corp | Gyrdjwy | Dwyllcs | $107.6 Bil | |
MDT
| Medtronic PLC | Zbqgbmjx | Fkfhqrs | $105.9 Bil | |
DXCM
| DexCom Inc | Sslsxhzws | Xpw | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Rmggmkdj | Zkptm | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Bltqlxxn | Xzmkb | $24.6 Bil | |
ALGN
| Align Technology Inc | Wzsyfltpd | Bxhjz | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Gyzsvds | Bcfbnp | $18.7 Bil | |
PODD
| Insulet Corp | Bjrrrlqch | Jczsd | $11.6 Bil |